GW&K Investment Management LLC Reduces Position in Insmed Incorporated (NASDAQ:INSM)

GW&K Investment Management LLC trimmed its stake in Insmed Incorporated (NASDAQ:INSM) by 1.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,135,393 shares of the biopharmaceutical company’s stock after selling 18,122 shares during the quarter. GW&K Investment Management LLC owned approximately 0.63% of Insmed worth $78,387,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. V Square Quantitative Management LLC raised its position in shares of Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 248 shares during the last quarter. Spire Wealth Management purchased a new stake in shares of Insmed in the fourth quarter valued at $47,000. Venturi Wealth Management LLC purchased a new stake in shares of Insmed in the fourth quarter valued at $86,000. Quantbot Technologies LP acquired a new position in Insmed in the third quarter valued at $133,000. Finally, Avior Wealth Management LLC purchased a new position in Insmed during the fourth quarter worth about $157,000.

Insider Transactions at Insmed

In other news, CFO Sara Bonstein sold 3,470 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $65.70, for a total transaction of $227,979.00. Following the completion of the transaction, the chief financial officer now directly owns 114,736 shares in the company, valued at approximately $7,538,155.20. This represents a 2.94 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $69.91, for a total transaction of $1,310,812.50. Following the sale, the chief executive officer now directly owns 384,960 shares of the company’s stock, valued at $26,912,553.60. The trade was a 4.64 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 532,207 shares of company stock valued at $41,400,465. 4.60% of the stock is currently owned by insiders.

Insmed Trading Up 1.2 %

INSM opened at $79.05 on Friday. The firm has a market capitalization of $14.31 billion, a P/E ratio of -14.14 and a beta of 1.11. The firm’s 50 day moving average is $74.66 and its 200-day moving average is $73.73. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Analysts expect that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on INSM. Stifel Nicolaus lowered their price target on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a report on Friday, February 21st. Wells Fargo & Company boosted their target price on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a report on Wednesday, February 19th. Morgan Stanley increased their price target on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. Guggenheim reiterated a “buy” rating and issued a $101.00 price target on shares of Insmed in a report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Insmed in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $91.60.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.